KeyBanc lowered the firm’s price target on Hinge Health (HNGE) to $55 from $70 and keeps an Overweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HNGE:
- Hinge Health price target lowered to $53 from $65 at Canaccord
- Hinge Health: Strong Beat, Operating Leverage, and Cash Generation Create an Attractive Long‑Term Buy After Share Pullback
- Hinge Health Posts Record 2025 Results With Strong Profitability
- Hinge Health reports Q4 EPS 49c, consensus 43c
- Hinge Health sees Q1 revenue $171M-$173M, consensus $159.67M